Size : 50mg
Phone : +1 850 650 7790
Synonyms: Baicalein 7-O-β-D-glucuronide
| Description | Baicalin (Baicalein 7-O-β-D-glucuronide) is a prolyl endopeptidase inhibitor isolated from Scutellaria baicalensis that exhibits anti-inflammatory, antioxidant, antitumor, and antiviral activity. Baicalin can be used in research on inflammation, neurodegenerative diseases, tumors, and metabolic syndrome. |
| In vitro | Methods: RAW264.7 cells were treated with baicalin (12.5, 25, 50 μM) for 24 hours. Surface CD14 and TLR4 proteins were detected by flow cytometry, and CD14 mRNA was detected by RT-qPCR. Results: Baicalin dose-dependently inhibited CD14 protein and mRNA expression without affecting TLR4 expression. [1] |
| In vivo | Methods: C57BL/6 mice were established with ulcerative colitis (UC) by free access to a 3% DSS solution for 5 days. Following modeling, Baicalin (100 mg/kg) was administered orally via gavage once daily for 5 consecutive days. Results: Baicalin treatment restored colon length, reduced spleen index, alleviated ulcer severity, and significantly suppressed CD14 and IL-6 expression in colonic mucosa. [1] Methods: Adult male SD rats received continuous oral administration of Baicalin (20, 60, 120 mg/kg) once daily for two weeks prior to surgery. Following drug administration, the left anterior descending artery (LAD) was ligated for 45 minutes, followed by reperfusion for 180 minutes to establish an MI/RI model. Results: I/R significantly impaired cardiac function. Baicalin at 60 and 120 mg/kg significantly improved HR, LVSP, LVFS, and LVEF in a dose-dependent manner. [2] |
| Synonyms | Baicalein 7-O-β-D-glucuronide |
| Molecular Weight | 446.36 |
| Formula | C21H18O11 |
| Cas No. | 21967-41-9 |
| Smiles | OC1=C2C(OC(=CC2=O)C3=CC=CC=C3)=CC(O[C@@H]4O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]4O)=C1O |
| Relative Density. | 1.737 g/cm3 |
| Storage | Keep away from direct sunlight,Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 37 mg/mL (82.89 mM), Sonication is recommended.  Ethanol: < 1 mg/mL (insoluble or slightly soluble) H2O: < 1 mg/mL (insoluble or slightly soluble) | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (8.96 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
